(BMEZ) BlackRock Health Sciences - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US09260E1055
Stock: Biotech, Pharmaceutical, Medical Device, Healthcare
Total Rating 42
Risk 82
Buy Signal 0.22
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 12.37% |
| Yield on Cost 5y | 11.35% |
| Yield CAGR 5y | 2.23% |
| Payout Consistency | 98.1% |
| Payout Ratio | 846.8% |
| Risk 5d forecast | |
|---|---|
| Volatility | 16.5% |
| Relative Tail Risk | -2.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.08 |
| Alpha | -7.70 |
| Character TTM | |
|---|---|
| Beta | 0.560 |
| Beta Downside | 0.661 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.41% |
| CAGR/Max DD | 0.48 |
Description: BMEZ BlackRock Health Sciences January 17, 2026
BlackRock Health Sciences Trust II (NYSE:BMEZ) is a U.S.-based common stock that operates within the Health Care Services sub-industry of the GICS classification.
Key metrics to watch include its dividend yield, which currently sits around 6-7%-attractive for income-focused investors-and its portfolio turnover rate, typically under 10%, indicating a relatively stable asset base. The trust’s performance is closely tied to macro-level health spending trends; for example, the U.S. Centers for Medicare & Medicaid Services projects a 5% annual growth in health care expenditures through 2028, bolstering demand for the services held in BMEZ’s portfolio.
For a deeper quantitative dive, you might explore ValueRay’s analytics platform, which offers granular, real-time data that can help you assess whether BMEZ aligns with your risk-adjusted return objectives.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 43.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 3.79 > 1.0 |
| NWC/Revenue: 44.75% < 20% (prev 24.88%; Δ 19.86% < -1%) |
| CFO/TA 0.09 > 3% & CFO 70.3m > Net Income 43.5m |
| Net Debt (-71.3k) to EBITDA (43.5m): -0.00 < 3 |
| Current Ratio: 153.7 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (13.3m) vs prev -4.94% < -2% |
| Gross Margin: 89.79% > 18% (prev 3.52%; Δ 8627 % > 0.5%) |
| Asset Turnover: 8.54% > 50% (prev 1.35%; Δ 7.19% > 0%) |
| Interest Coverage Ratio: -100.0k > 6 (EBITDA TTM 43.5m / Interest Expense TTM 78.0) |
Altman Z'' 10.00
| A: 0.03 (Total Current Assets 26.6m - Total Current Liabilities 172.8k) / Total Assets 774.6m |
| B: -0.22 (Retained Earnings -173.5m / Total Assets 774.6m) |
| C: -0.03 (EBIT TTM -21.5m / Avg Total Assets 690.4m) |
| D: 129.5 (Book Value of Equity 768.6m / Total Liabilities 5.93m) |
| Altman-Z'' Score: 135.3 = AAA |
What is the price of BMEZ shares?
As of February 07, 2026, the stock is trading at USD 15.05 with a total of 373,512 shares traded.
Over the past week, the price has changed by -1.05%, over one month by -0.60%, over three months by +5.43% and over the past year by +3.99%.
Over the past week, the price has changed by -1.05%, over one month by -0.60%, over three months by +5.43% and over the past year by +3.99%.
Is BMEZ a buy, sell or hold?
BlackRock Health Sciences has no consensus analysts rating.
What are the forecasts/targets for the BMEZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 17.1 | 13.8% |
BMEZ Fundamental Data Overview February 02, 2026
P/S = 23.3725
P/B = 0.9917
Revenue TTM = 59.0m USD
EBIT TTM = -21.5m USD
EBITDA TTM = 43.5m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 278.1k USD (from shortTermDebt, last quarter)
Debt = 278.1k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -71.3k USD (from netDebt column, last quarter)
Enterprise Value = 1.51b USD (1.54b + Debt 278.1k - CCE 26.6m)
Interest Coverage Ratio = -276.2k (Ebit TTM -21.5m / Interest Expense TTM 78.0)
EV/FCF = 21.54x (Enterprise Value 1.51b / FCF TTM 70.3m)
FCF Yield = 4.64% (FCF TTM 70.3m / Enterprise Value 1.51b)
FCF Margin = 119.2% (FCF TTM 70.3m / Revenue TTM 59.0m)
Net Margin = 73.72% (Net Income TTM 43.5m / Revenue TTM 59.0m)
Gross Margin = 89.79% ((Revenue TTM 59.0m - Cost of Revenue TTM 6.02m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.95 (Enterprise Value 1.51b / Total Assets 774.6m)
Interest Expense / Debt = 0.03% (Interest Expense 78.0 / Debt 278.1k)
Taxrate = 21.0% (US default 21%)
NOPAT = -17.0m (EBIT -21.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 153.7 (out of range, set to none) (Total Current Assets 26.6m / Total Current Liabilities 172.8k)
Debt / Equity = 0.00 (Debt 278.1k / totalStockholderEquity, last quarter 768.6m)
Debt / EBITDA = -0.00 (Net Debt -71.3k / EBITDA 43.5m)
Debt / FCF = -0.00 (Net Debt -71.3k / FCF TTM 70.3m)
Total Stockholder Equity = 642.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.30% (Net Income 43.5m / Total Assets 774.6m)
RoE = 6.77% (Net Income TTM 43.5m / Total Stockholder Equity 642.6m)
RoCE = -3.35% (EBIT -21.5m / Capital Employed (Equity 642.6m + L.T.Debt 0.0))
RoIC = -2.29% (negative operating profit) (NOPAT -17.0m / Invested Capital 742.3m)
WACC = 7.98% (E(1.54b)/V(1.54b) * Re(7.98%) + D(278.1k)/V(1.54b) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -58.80%
[DCF Debug] Terminal Value 81.33% ; FCFF base≈55.0m ; Y1≈67.8m ; Y5≈115.5m
Fair Price DCF = 31.37 (EV 1.96b - Net Debt -71.3k = Equity 1.96b / Shares 62.5m; r=7.98% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -54.13 | EPS CAGR: -91.43% | SUE: 0.11 | # QB: 0
Revenue Correlation: -17.93 | Revenue CAGR: 67.56% | SUE: N/A | # QB: 0
P/B = 0.9917
Revenue TTM = 59.0m USD
EBIT TTM = -21.5m USD
EBITDA TTM = 43.5m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 278.1k USD (from shortTermDebt, last quarter)
Debt = 278.1k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -71.3k USD (from netDebt column, last quarter)
Enterprise Value = 1.51b USD (1.54b + Debt 278.1k - CCE 26.6m)
Interest Coverage Ratio = -276.2k (Ebit TTM -21.5m / Interest Expense TTM 78.0)
EV/FCF = 21.54x (Enterprise Value 1.51b / FCF TTM 70.3m)
FCF Yield = 4.64% (FCF TTM 70.3m / Enterprise Value 1.51b)
FCF Margin = 119.2% (FCF TTM 70.3m / Revenue TTM 59.0m)
Net Margin = 73.72% (Net Income TTM 43.5m / Revenue TTM 59.0m)
Gross Margin = 89.79% ((Revenue TTM 59.0m - Cost of Revenue TTM 6.02m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.95 (Enterprise Value 1.51b / Total Assets 774.6m)
Interest Expense / Debt = 0.03% (Interest Expense 78.0 / Debt 278.1k)
Taxrate = 21.0% (US default 21%)
NOPAT = -17.0m (EBIT -21.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 153.7 (out of range, set to none) (Total Current Assets 26.6m / Total Current Liabilities 172.8k)
Debt / Equity = 0.00 (Debt 278.1k / totalStockholderEquity, last quarter 768.6m)
Debt / EBITDA = -0.00 (Net Debt -71.3k / EBITDA 43.5m)
Debt / FCF = -0.00 (Net Debt -71.3k / FCF TTM 70.3m)
Total Stockholder Equity = 642.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.30% (Net Income 43.5m / Total Assets 774.6m)
RoE = 6.77% (Net Income TTM 43.5m / Total Stockholder Equity 642.6m)
RoCE = -3.35% (EBIT -21.5m / Capital Employed (Equity 642.6m + L.T.Debt 0.0))
RoIC = -2.29% (negative operating profit) (NOPAT -17.0m / Invested Capital 742.3m)
WACC = 7.98% (E(1.54b)/V(1.54b) * Re(7.98%) + D(278.1k)/V(1.54b) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -58.80%
[DCF Debug] Terminal Value 81.33% ; FCFF base≈55.0m ; Y1≈67.8m ; Y5≈115.5m
Fair Price DCF = 31.37 (EV 1.96b - Net Debt -71.3k = Equity 1.96b / Shares 62.5m; r=7.98% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -54.13 | EPS CAGR: -91.43% | SUE: 0.11 | # QB: 0
Revenue Correlation: -17.93 | Revenue CAGR: 67.56% | SUE: N/A | # QB: 0